Panion's emission is finalised and the dog safety study is progressing well

Panion's shares emission that was running from 16-30 May and raised appr. 5.2 MSEK before emission costs, has now been completed and all payments processed.

The CEO and three members of the management had signed up for buying shares in Panion in this emission, and this was finalized well for CEO Anja Holm and board member Lars Friis Mikkelsen. However, for board member Dede Willis and Director of Business development Carlos N Velez, the American banks could not handle the requested transactions via AktieTorget, and these two subscriptions had to be cancelled. Instead the shares are sold to Swedish investors.

"This is very unfortunate, because we certainly would have liked to include these two leading profiles on the list of shareholders", says CEO Anja Holm, "but we appreciate all the effort that was put into finding solutions for a very complex situation."

Panion is currently running a safety study in dogs with the innovative product candidate GC01-canine in cooperation with the University of Copenhagen under the lead of associate professor David Woldbye, Department of Neuroscience.

"The study is progressing well, and the animal phase is so far without negative or unforeseen events for all dogs in the study. We are very pleased with the development and look forward to finalizing the animal phase according to plan, so we can report the results to the market as soon as possible" says CEO Anja Holm. "The coming steps in the development plan is a pilot clinical study in client-owned dogs, which have drug-resistant epilepsy".

JULY 31 2018

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Kommuniké från årsstämma i Panion Animal Health AB (publ)

Idag, den 23 april 2019, hölls årsstämma i Panion Animal Health AB. Nedan följer en sammanfattning av de beslut som fattades vid årsstämman.


CombiGene lämnar ett offentligt uppköpserbjudande till innehavarna av aktier och teckningsoptioner av serie TO1 i Panion Animal Health

CombiGene AB (publ) ("CombiGene") har idag lämnat ett offentligt uppköpserbjudande till innehavarna av aktier ("Aktierna) och teckningsoptioner av serie TO1 med ISIN-kod SE0011205343 ("Teckningsoptionerna") i Panion Animal Health AB (publ) ("Panion" eller "Bolaget") att överlåta samtliga sina Aktier och Teckningsoptioner till CombiGene ("Erbjudandet"). Aktierna och Teckningsoptionerna är upptagna till handel på Spotlight Stock Market ("Spotlight").



Kommentar avseende revisorns anmärkning i publicerad årsredovisning för 2018

Angående revisorns anmärkning i årsredovisning 2018




Kallelse till årstämma i Panion Animal Health AB

Aktieägarna i Panion Animal Health AB (publ), org.nr 559018-4171, kallas härmed till årsstämma tisdagen den 23 april 2019 kl. 14.00 på Mazars SET Revisionsbyrå ABs kontor, Scheelevägen 17, i Lund.



PM Technical investigator meeting in Copenhagen

Panion develops a gene therapy treatment for dogs with epilepsy. The clinical trial in dogs with real epilepsy will take place in the large investigator clinic, Long Island Veterinary Specialists (LIVS) in New York, USA. The study procedures are advancing well in accordance with the plan. The vector material is produced and undergoing testing procedures.



New advisory board member


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär